The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
about
Comorbidities of idiopathic thrombocytopenic purpura: a population-based studyCurrent Management of Primary Immune ThrombocytopeniaSevere bleeding events in adults and children with primary immune thrombocytopenia: a systematic reviewImmune thrombocytopeniaContemporary management of primary immune thrombocytopenia in adultsHelicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of BiogeographyAdvances in ITP--therapy and quality of life--a patient surveyGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Is admission for epistaxis more common in Caucasian than in Asian people? A preliminary study.Management of adult immune thrombocytopenia.Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis.Unprovoked periodontal hemorrhage, life-threatening anemia and idiopathic thrombocytopenia purpura: an unusual case report.Adult idiopathic thrombocytopenic purpura.Autoimmune thrombocytopenia.The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients.A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation.Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China.Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisImpact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective.Repeated courses of rituximab in chronic ITP: Three different regimens.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Pathophysiology and therapeutic options in primary immune thrombocytopenia.Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.Decision modeling of disagreements: pediatric hematologists' management of idiopathic thrombocytopenic purpura.The development of romiplostim for patients with immune thrombocytopenia.Eltrombopag for the treatment of immune thrombocytopenia.Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study.Ischemic stroke in the setting of chronic immune thrombocytopenia in an elderly patient--a therapeutic dilemma.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.Patient-reported treatment burden of chronic immune thrombocytopenia therapies.Risk and prognosis of adult primary immune thrombocytopenia.Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
P2860
Q21328697-5E147580-EB0E-4CEC-84E0-FB89B0273EB9Q26779408-959873D8-FFFC-4973-9824-9864AC2C4BF0Q26826853-295F32F5-A545-4C53-8528-2BF0AC75F280Q26830918-35E1BE3A-6094-4330-8318-6470C0DBCCA8Q26853680-83DFF2A2-44AC-4C16-A14F-1233EADD8D17Q26865062-CCFB2258-59F5-4391-BC31-D63ACA40C778Q28742871-A1E33338-49E6-41A6-B2A8-9093F280C5C9Q30276550-532A4EC2-96C5-46D1-B0B3-CB8DF64CF97CQ33259079-030B4F5C-BCD2-4AAA-9BA8-272781E04730Q33339746-BDACEA8D-5FE5-4D3A-914E-510C48ABC427Q33343948-28099168-916C-4D14-94C0-B58E1F9F20FFQ33346561-3A769147-F625-48FD-A119-F8F52865A1BFQ33347074-16E4D380-228A-4322-8721-BE84A43009D1Q33357642-1DFDF6E1-4F98-4C0C-BF6B-1BC41990F4AAQ33358032-30EF5A37-A759-479F-AF5E-5A9D0FDF83B6Q33367861-3266E10A-8F3D-4317-BCFA-873ABE51BA46Q33368951-13F0A8B6-B543-46EC-9F2F-E08FF64449D8Q33369925-F01A7165-4A3A-4549-9F60-E80ECC5F0A96Q33374327-52185568-D8FE-449A-910B-06757DC0DCEDQ33374847-6BC00389-72D3-4DA8-B8F6-6709957FD10BQ33376705-BF454C21-B644-4D96-B428-A43FEDED9BC6Q33378585-051C1664-F3D8-4733-B459-91A0416D3F54Q33386117-3DFFB81F-B74B-4122-9D2B-76E4C8D6AE57Q33391221-57A6223C-1A7B-4B1C-ADF5-098A28B77F62Q33392852-8E29BCE9-406F-46BB-ACD3-AE48F7083DFDQ33392868-6B7DA994-92AA-49CD-8F8B-2B4EB38AAD48Q33393732-2B01FEFC-077C-429D-BFC2-1097D24C09F8Q33394438-77DC90D0-29CE-4D32-BB83-AB8B7677CFCDQ33394489-FF3C34DF-082C-48A0-A752-8B8F4FCDCC02Q33394636-CAE23698-ACEC-4F2C-9BFE-2A9B0807F562Q33395776-C6A49000-76BB-4C89-80BD-4B1244CD8540Q33396252-FB6D5C5E-E144-43E6-8260-A1059112D277Q33396902-CF4949D2-9FD0-49E7-AD61-609AF83A168AQ33397388-CD5AFCBE-F77A-4D1C-A684-31DCB7006DA1Q33398252-A9AE109F-2757-42CC-87C2-110C71E75E69Q33400018-621BEA84-1FA9-4975-8A15-17447C6156AFQ33400203-E163014B-734C-4EBC-895C-D08065E2B8B5Q33400348-E30D3AB8-3EE3-434B-AFE0-995299C4AC8FQ33400566-CC619AF1-356A-417D-BED3-EB8F2C4E532DQ33400722-935910D1-19E5-4804-BEB2-BCA2B8B7AC5C
P2860
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The bleeding risk and natural ...... ersistent low platelet counts.
@ast
The bleeding risk and natural ...... ersistent low platelet counts.
@en
The bleeding risk and natural ...... ersistent low platelet counts.
@nl
type
label
The bleeding risk and natural ...... ersistent low platelet counts.
@ast
The bleeding risk and natural ...... ersistent low platelet counts.
@en
The bleeding risk and natural ...... ersistent low platelet counts.
@nl
prefLabel
The bleeding risk and natural ...... ersistent low platelet counts.
@ast
The bleeding risk and natural ...... ersistent low platelet counts.
@en
The bleeding risk and natural ...... ersistent low platelet counts.
@nl
P2093
P921
P1476
The bleeding risk and natural ...... ersistent low platelet counts.
@en
P2093
Djulbegovic B
Shamai-Lubovitz O
P304
P356
10.1001/ARCHINTE.160.11.1630
P407
P577
2000-06-01T00:00:00Z